
REMEVi Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 8.1/10
Best for: Spanish-speaking patients who want bilingual compounded GLP-1 care with labs included
REMEVi scores highest on state availability and ease of access.
Semaglutide
Tirzepatide
Price checked on REMEVi’s site,
What the monthly price covers
Medication
Included
Provider visits
Included
Shipping
Included
Lab work
Included
Coaching
Not stated
No insurance needed · Vetted by our editors
REMEVi is a bilingual (English and Spanish) GLP-1 telehealth clinic where every step, from intake to care coordination, is available in either language. It offers compounded semaglutide injections at $199 every 4 weeks, oral semaglutide tablets at $249, and tirzepatide at $269, with lower rates on prepaid 12- and 24-week plans. One price covers care, medication, clinician-required labs, supplies and shipping, at every dose. It names its four partner pharmacies and serves 49 states plus DC (not Louisiana).
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Vetted alternatives to REMEVi
Ro
Best for: FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Editorial score · methodology
Collective
Best for: the lowest flat medication price if you can absorb an annual membership fee
Editorial score · methodology
CoreAge Rx
Best for: lowest-price compounded semaglutide and tirzepatide with one flat price at every dose
Editorial score · methodology
REMEVi at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide, Oral Semaglutide Tablets
- Starting price
- $199/4 wks (billed per 4 weeks)
- Pricing model
- Flat: dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping · Labs
- Availability
- 49 states + DC
- FDA status
- No FDA warning letter on record
How we scored REMEVi
Each dimension is scored algorithmically from REMEVi’s published pricing, drugs offered, verification status, and disclosed inclusions, using the same six-dimension framework we apply to every provider.
Value25%
7.7/10At $199/mo (per 4 weeks), REMEVi runs about 11% above the $179 median for GLP-1 providers (each program's lowest listed ongoing monthly price for compounded semaglutide). Pricing is flat across doses, so there is no escalation markup as you titrate up.
Effectiveness25%
8.7/10REMEVi offers both semaglutide and tirzepatide, the two GLP-1 molecules with the strongest published weight-loss trial outcomes. An oral/needle-free option is offered for patients who avoid injections.
User Experience15%
7.9/10Online intake and platform experience (consult included in the price); 8 platform features disclosed.
Trust & Safety15%
8.6/10Key details fully confirmed by our editors; no FDA warning letters on file.
Accessibility10%
8.8/10REMEVi is available in 49 states plus DC: all but Louisiana.
Support10%
6.4/10REMEVi provides standard clinician follow-up; no extended coaching or community program is disclosed.
Each checked against the provider’s own site.
Providers that don’t post pricing up front score lower on Value and carry a cost-transparency note in their review. Read the full methodology →
How we verified this REMEVi review
Last checked October 2026- Confirmed current pricing across 3 dose/plan tiers
- Confirmed availability in 49 states plus DC
- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the provider's public sign-up flow, stopping before payment
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records. See the sources below. Editorial confidence in this data: high.
What we checked
- Provider's own pricing page
- $199–$269/mo across 3 dose/plan tiers (checked October 2026)
- State pharmacy licensing & LegitScript status
- LegitScript Verified
- FDA warning-letter register
- No letter on file for this provider
What to expect when you sign up with REMEVi
We walked REMEVi’s public signup flow in October 2026 to document the process (the steps, pricing transparency, and what’s required) before you commit. (We don’t create accounts, enter medical information, or check out; this is the observable funnel, not a prescribing outcome.)
- 1Click See if I qualify to open the questionnaire, which shows four stages: Getting started, Your health, Your plan, Checkout.
- 2Pick what you are hoping to get back (energy, confidence, a health concern, feeling like yourself); the screen lists all plan prices.
- 3Enter your height and current weight (we stopped here).
- 4Answer health questions, choose a plan, and pay at checkout; a licensed clinician then reviews your case, usually within 24 hours.
- Prices appear before any questions: semaglutide from $159 every 4 weeks (24-week plan) or $199 with no commitment, tirzepatide $225 or $269, pills $215 or $249.
- Billing is every 4 weeks, and the pricing page says so plainly: 'Four weeks is 28 days, not a calendar month.'
- The 12- and 24-week rates are charged upfront in full and renew at the end of the term.
- No card is needed to start, but payment comes at checkout before the clinician review; you get a full refund if you are not prescribed.
- Cancel by email or in your account at least 72 hours before your billing date; prepaid plans refund months with no medication shipped.
- The site names its partner pharmacies (RedRock, Health Warehouse, Precision Medicine, Triad Rx) with license lookups.
- Everything, including the questionnaire, is available in Spanish.
REMEVi customer support
- Phone
- (702) 352-4746
- Hours
- Mon-Fri 9am-6pm ET
GLP-1 medications REMEVi offers
Tap any medication to read our plain-English guide: how it works, dosing, side effects, and what the trials found.
Peptides REMEVi offers
Beyond GLP-1s, REMEVi also offers these peptides. Tap any for our evidence-based guide.
Pricing
Prices re-verified
$199 billed every 4 weeks, same at every dose. Longer plans: 12-wk $169/4 wk ($507 upfront), 24-wk $159/4 wk ($954 upfront).
$249 billed every 4 weeks, same at every dose. Longer plans: 12-wk $229/4 wk ($687 upfront), 24-wk $215/4 wk ($1,290 upfront).
$269 billed every 4 weeks, same at every dose. Longer plans: 12-wk $233/4 wk ($699 upfront), 24-wk $225/4 wk ($1,350 upfront).
Ready to get started?
Plans and promotions change often, so check REMEVi's current pricing and active discounts before you decide.
What we like
- Fully bilingual care: intake, clinicians and care coordinators available in English or Spanish
- Same price at every dose with no membership fee; care, medication, clinician-required labs, supplies and shipping included
- Names its four partner pharmacies with addresses and license lookups
- LegitScript-certified, with a seal you can look up on LegitScript's own site
- Free questionnaire with no card to start; full refund if you are not prescribed
- Prepaid 12- and 24-week plans lower the rate to as little as $159 every 4 weeks for semaglutide
- Offers oral semaglutide tablets as a needle-free option
Watch-outs
- Billed every 4 weeks, not monthly, so the every-4-weeks plan means 13 charges a year
- The lowest advertised rates require paying 12 or 24 weeks upfront, and those plans renew
- Not available in Louisiana
- Compounded medications are not FDA-approved (the site discloses this), not brand Wegovy or Zepbound
- On the every-4-weeks plan, the cycle you cancel in is not refunded; cancel 72+ hours before billing
- A newer clinic; you pay at checkout before the clinician review
Is REMEVi worth it?
REMEVi is aimed squarely at Spanish-speaking patients who want bilingual compounded GLP-1 care with labs included. It runs $199/month (per 4 weeks) at every dose. That is a qualified figure, not a plain month-to-month price, so we don't rank it against the category median; the cost section below says what it covers. Its standout is a needle-free oral option for people who would rather not inject.
It offers care in Spanish. It also is LegitScript-certified and includes lab testing.
How much REMEVi costs
Compounded semaglutide runs $199–$249/month depending on plan, the low end listed as “per 4 weeks”, and compounded tirzepatide runs $269/month (per 4 weeks).
Because REMEVi's headline figure is listed as “per 4 weeks”, we don't set it against the roughly $179 market median for this category. That median is each program's lowest listed ongoing monthly price for compounded semaglutide, so compare REMEVi with the month-to-month prices of the alternatives below instead.
Belle Health (about $199/month) is one of the closest alternatives to weigh REMEVi against.
Medications: what REMEVi prescribes
REMEVi prescribes semaglutide (the active drug in Wegovy and Ozempic) and tirzepatide (the active drug in Zepbound and Mounjaro), the two molecules with the strongest published weight-loss trial outcomes. These are dispensed as compounded formulations from a licensed pharmacy, which is how the price stays below brand-name pens. Compounded drugs aren't FDA-approved as finished products, which is the standard trade-off across the compounded-GLP-1 market.
REMEVi's needle-free oral option appeals if you've been avoiding a GLP-1 because of injections. Just set expectations on the science: oral, sublingual and buccal delivery of these peptides is far less studied than the injectable versions the trials used. Treat it as a convenience option, not a proven equal to the shot.
Who REMEVi is best for, and who should skip it
A good fit if you…
- are needle-averse and want a non-injectable option, since the oral route skips the weekly injection most GLP-1 programs require.
Look elsewhere if you…
- specifically want an FDA-approved brand-name pen instead of a compounded formulation, which this provider doesn't fill.
- need to bill insurance, since like most of this market it's cash-pay with no claims filed on your behalf.
Trust, safety, and medical oversight
REMEVi is available in 49 states, and we found no FDA warning letter on file for it. As with any compounded program, the most important step you can take is confirming which licensed pharmacy fills your prescription and what's in the formulation, and we explain how in our scoring methodology.
Bottom line
REMEVi is a reasonable telehealth GLP-1 option; weigh its pricing and coverage against the alternatives below before deciding. To see REMEVi against the wider field, use our ranking of semaglutide providers; the patient guide to compounded versus brand-name GLP-1s covers what to weigh before choosing a compounded program.
The Bottom Line
REMEVi scores highest on state availability and ease of access.
Ready to start with REMEVi?
From $199/4 wks (billed per 4 weeks). See current pricing and start your free consultation.
REMEVi might not be your best fit if…
We rank editorially, so here’s where a different provider we track may serve you better.
Head-to-head
Compare REMEVi vs…
REMEVi scores8.1/10
Side-by-side pricing, medications and scores. Pick a matchup.
REMEVi vs Amazon One Medical
Amazon One Medical scores 8.5/10

REMEVi vs Vytora Health
Vytora Health scores 8.4/10
Scores are our independent editorial ratings out of 10.
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this REMEVi review:
Sources & methodology (as of November 2026)
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See REMEVi's current pricing
Plans from $199/4 wks (billed per 4 weeks). Start your free consultation to check eligibility and today's price.